These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35703302)

  • 21. Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era.
    de Miguel S; Domenech M; González-Camacho F; Sempere J; Vicioso D; Sanz JC; Comas LG; Ardanuy C; Fenoll A; Yuste J
    Clin Infect Dis; 2021 Dec; 73(11):e3778-e3787. PubMed ID: 32990303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.
    Bruce MG; Singleton R; Bulkow L; Rudolph K; Zulz T; Gounder P; Hurlburt D; Bruden D; Hennessy T
    Vaccine; 2015 Sep; 33(38):4813-9. PubMed ID: 26247901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
    Link-Gelles R; Taylor T; Moore MR;
    Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.
    Moore CE; Paul J; Foster D; Mahar SA; Griffiths D; Knox K; Peto TE; Walker AS; Crook DW;
    J Infect Dis; 2014 Oct; 210(7):1001-11. PubMed ID: 24719477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13.
    Redin A; Ciruela P; de Sevilla MF; Gomez-Bertomeu F; Gonzalez-Peris S; Benitez MA; Trujillo G; Diaz A; Jou E; Izquierdo C; Perez-Moreno MO; Moraga-Llop F; Olsina M; Vinado B; Sanfeliu E; Garcia A; Gonzalez-di Lauro S; Garcia-Garcia JJ; Dominguez A; Sa-Leao R; Muñoz-Almagro C;
    Microbiol Spectr; 2021 Dec; 9(3):e0115021. PubMed ID: 34878302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study.
    Lo SW; Gladstone RA; van Tonder AJ; Lees JA; du Plessis M; Benisty R; Givon-Lavi N; Hawkins PA; Cornick JE; Kwambana-Adams B; Law PY; Ho PL; Antonio M; Everett DB; Dagan R; von Gottberg A; Klugman KP; McGee L; Breiman RF; Bentley SD;
    Lancet Infect Dis; 2019 Jul; 19(7):759-769. PubMed ID: 31196809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of vaccination on the burden of invasive pneumococcal disease from a nationwide surveillance program in Lebanon: an unexpected increase in mortality driven by non-vaccine serotypes.
    Reslan L; Youssef N; Boutros CF; Assaf-Casals A; Fayad D; Khafaja S; Akl F; Finianos M; Rizk AA; Shaker R; Zaghlout A; Lteif M; El Hafi B; Moumneh MB; Feghali R; Ghanem S; Jisr T; Karayakoupoglou G; Naboulsi M; Hamze M; Samad S; Khoury E; Sarraf R; Osman M; Bou Raad E; El Amin H; Abadi I; Abdo H; Chedid M; Chamseddine F; Barakat A; Houmani M; Haddad A; Abdel Nour G; Mokhbat JE; Daoud Z; El-Zaatari M; Salem Sokhn E; Ghosn N; Ammar W; Hamadeh R; Matar GM; Araj GF; Dbaibo GS
    Expert Rev Vaccines; 2022 Dec; 21(12):1905-1921. PubMed ID: 36342411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumococcal carriage in households in Karonga District, Malawi, before and after introduction of 13-valent pneumococcal conjugate vaccination.
    Heinsbroek E; Tafatatha T; Phiri A; Swarthout TD; Alaerts M; Crampin AC; Chisambo C; Mwiba O; Read JM; French N
    Vaccine; 2018 Nov; 36(48):7369-7376. PubMed ID: 30352744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
    Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
    Vaccine; 2023 Aug; 41(38):5662-5669. PubMed ID: 37544825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
    PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine.
    Satzke C; Dunne EM; Choummanivong M; Ortika BD; Neal EFG; Pell CL; Nation ML; Fox KK; Nguyen CD; Gould KA; Hinds J; Chanthongthip A; Xeuatvongsa A; Mulholland EK; Sychareun V; Russell FM
    Vaccine; 2019 Jan; 37(2):296-305. PubMed ID: 30502068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
    Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
    J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine.
    Martínez-Osorio J; García-García JJ; Moraga-Llop F; Díaz A; Hernández S; Solé-Ribalta A; González-Peris S; Izquierdo C; Esteva C; Codina G; Planes AM; Uriona S; Campins M; Ciruela P; Salleras L; Domínguez Á; Muñoz-Almagro C; de Sevilla MF
    An Pediatr (Engl Ed); 2022 Jun; 96(6):501-510. PubMed ID: 34238710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
    Wijayasri S; Hillier K; Lim GH; Harris TM; Wilson SE; Deeks SL
    PLoS One; 2019; 14(12):e0226353. PubMed ID: 31834926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
    Kendall BA; Dascomb KK; Mehta RR; Stockmann C; Mason EO; Ampofo K; Pavia AT; Byington CL
    Vaccine; 2016 Jan; 34(4):474-478. PubMed ID: 26706276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
    Ciruela P; Izquierdo C; Broner S; Muñoz-Almagro C; Hernández S; Ardanuy C; Pallarés R; Domínguez A; Jané M;
    Vaccine; 2018 Nov; 36(50):7744-7752. PubMed ID: 30473132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe.
    Hanquet G; Krizova P; Dalby T; Ladhani SN; Nuorti JP; Danis K; Mereckiene J; Knol MJ; Winje BA; Ciruela P; de Miguel S; Portillo ME; MacDonald L; Morfeldt E; Kozakova J; Valentiner-Branth P; Fry NK; Rinta-Kokko H; Varon E; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Henriques-Normark B; Colzani E; Pastore-Celentano L; Savulescu C;
    Emerg Infect Dis; 2022 Jan; 28(1):137-138. PubMed ID: 34932457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.